Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Aug 25;140(8):927–931. doi: 10.1182/blood.2022016642

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology

PMC Copyright notice

Figure 2. — Clinical (and hematological) outcome of patients with VEXAS syndrome treated with JAKi. (A) Kaplan-Meier representation of the time to next treatment in patients treated by ruxolitinib or other JAKi. (B) Prednisone dose (percentage of baseline) after 1, 3, and 6 months in patients treated with ruxolitinib or other JAKi. (C-D) Hemoglobin and platelet count evolution at baseline and after 1 and 3 months of ruxolitinib in patients treated with ruxolitinib or other JAKi. (E) UBA1 fish plot of 2 patients treated with ruxolitinib.